NCT07237009 · RECRUITING
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
This study tests whether using a reminiscence app for 10-15 minutes a day over 25 days eases apathy and low mood in people with mild memory or thinking problems. A digital conversational agent guides each session, using family memories a caregiver shares. The phase isn't specified, so treat it as early, exploratory research.
You may qualify if
- Men and women over 60 years of age.
- DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes.
- Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28.
- Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both
- Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool.
- Having voluntarily and informedly agreed to participate in the study (signed written consent).
- Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool).
- Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access.
- Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group.
- Subjects covered by a social security scheme.
You're excluded if
- Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD.
- Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder).
- Major hearing or visual impairments.
- History of premorbid intellectual disability.
- Patients under guardianship, conservatorship, or legal protection.
- Patients who have already used the Lilia app
- Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study.
- Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-09